Interleukin-33: a novel player in osteonecrosis of the femoral head?
Related Experiment Video
Updated: May 31, 2026
Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
Published on: September 27, 2024
1Inserm UMR-S 606, hôpital Lariboisière, Paris, France.
Insights
Interleukin-33 (IL-33) may be a new therapeutic target for osteonecrosis of the femoral head (ONFH). This disabling hip disease involves bone cell death due to poor blood supply, and IL-33 is released by necrotic cells.
Area of Science:
- Orthopedics and Bone Biology
- Immunology and Inflammation
Background:
- Osteonecrosis of the femoral head (ONFH) is a debilitating condition in young adults, often leading to hip joint destruction.
- The primary cause is impaired blood supply, resulting in osteocyte and bone marrow cell death.
- Current joint-salvaging treatments for ONFH are limited in efficacy, highlighting the need for novel therapeutic approaches.
Purpose of the Study:
- To investigate the potential role of interleukin-33 (IL-33) as a therapeutic target in ONFH.
- To explore the expression and function of IL-33 in the context of bone cell necrosis and hip joint pathology.
Main Methods:
- Review of existing literature on IL-33, osteonecrosis, and bone cell biology.
- Analysis of studies reporting IL-33 expression in bone tissue and its modulation of angiogenesis and bone metabolism.
Main Results:
- IL-33 is an alarmin specifically released by necrotic cells.
- IL-33 is constitutively expressed in human bone by osteocytes, osteoblasts, and marrow adipocytes.
- Emerging evidence suggests IL-33 influences angiogenesis, vascular permeability, osteoclastogenesis, and bone resorption, implicating it in ONFH pathogenesis.
Conclusions:
- IL-33 presents a promising molecular target for developing new therapeutic strategies against ONFH.
- Further research is warranted to elucidate the precise mechanisms by which IL-33 contributes to ONFH and to evaluate its therapeutic potential.
Abstract:
Osteonecrosis of the femoral head (ONFH) is a disabling disease affecting young adults, which usually leads to the destruction of the hip joint. It is mainly due to an inadequate blood supply that causes the death of osteocytes and bone marrow cells. Joint salvaging procedures are numerous but relatively inefficient, justifying the need for new therapeutic strategies. In this regard, the recently discovered interleukin (IL)-33 alarmin appears as a possible target. Indeed, IL-33 seems to be specifically released by necrotic cells, and interestingly, is constitutively expressed in human bone, in particular by osteocytes, osteoblasts and marrow adipocytes. Moreover, recent reports suggesting that IL-33 modulates angiogenesis, vascular permeability, osteoclastogenesis and bone resorption, indicate that IL-33 may play a role in ONFH.